Alloy Therapeutics Partners with Sanofi to Advance Innovative Therapeutics in the CNS Space

Shots:

• Alloy Therapeutics and Sanofi have entered into a target specific partnership to leverage Alloy’s AntiClastic Antisense Platform for a CNS target
• Sanofi will utilize its neuroscience expertise to develop genetic medicines that cross the blood-brain barrier. It will pay up to $27.5M as upfront & near-term preclinical milestones as well as $400M as discovery, development & commercial milestones plus tiered royalties on resulting product sales
• Alloy’s AntiClastic Antisense platform enables RNA-level targeting of intracellular diseases, overcoming limitations in antisense therapeutic index

Ref: Alloy Therapeutics | Image: Alloy Therapeutics & Sanofi

Related News:- Pharmanovia Collaborates with Lindis Biotech to Commercialize Catumaxomab for Treating Malignant Ascites

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com